FUDAN FORWARD(600624)2025-01-23 09:40Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2024 to be between -120 million and -80 million RMB, indicating a loss compared to the previous year[2]. - The projected net profit excluding non-recurring gains and losses for 2024 is estimated to be between -127 million and -85 million RMB[3]. - In 2023, the total profit was approximately 23.48 million RMB, with a net profit attributable to shareholders of about 5.96 million RMB[4]. Factors Affecting Performance - The decline in performance is primarily due to changes in the pharmaceutical industry policies and a decrease in prices for key products, leading to a drop in revenue and net profit for the subsidiary Shanghai Fudan Fuhua Pharmaceutical Co., Ltd.[6]. - The company has identified impairment signs in its real estate projects, leading to preliminary impairment testing and expected asset impairment losses[6]. - Non-recurring gains and losses have decreased compared to 2023, mainly due to lower disposal gains from non-current assets[6]. Legal and Audit Considerations - The company is currently involved in two legal cases that may impact its financial performance, but the effects are not yet quantified in the earnings forecast[7][9]. - The earnings forecast data has not been audited by a registered accountant, and investors are advised to be cautious[10].